Table 2.
Demographic and clinical characteristics of patients receiving vitamin D screening by intervention period
| Demographic characteristics | Pre-implementation (n = 27 481) | Post-implementation (n = 8939) (%) | Significance, P value |
|---|---|---|---|
| Age (mean ± SD) | 54.3 ± 17.3 | 55.1 ± 17.7 | <.0001 |
| Female | 18 909 (68.8) | 6339 (70.9) | <.001 |
| Non-white race | 3050 (11.1) | 958 (10.7) | Not significant |
| Hypo- or hypercalcemia | 981 (3.6) | 533 (6.0) | <.001 |
| Hypo- or hyperparathyroidism | 546 (2.0) | 384 (4.3) | <.001 |
| Vitamin D deficiency or hypervitaminosis | 10 042 (36.5) | 4011 (44.9) | <.001 |
| Malabsorption | 1728 (6.3) | 1005 (11.2) | <.001 |
| Kidney disease | 3151 (11.5) | 1387 (15.5) | <.001 |
| Osteoporosis | 4139 (15.1) | 1682 (18.8) | <.001 |
| Antiepileptics | 154 (0.56) | 66 (0.74) | Not significant |
| Steroids | 2044 (7.4) | 793 (8.9) | <.001 |
| HIV antivirals | 144 (0.5) | 100 (1.1) | <.001 |